Kyverna Therapeutics Unveils Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial for Myasthenia Gravis at Virtual KOL Event

Kyverna Therapeutics is highlighting its neuroimmunology CAR T franchise in stiff person syndrome and myasthenia gravis. The company will share details of its Phase 3 clinical trial design in MG, positive follow-up data from MG and SPS compassionate use patients treated with KYV-101, and insights from leading KOLs on CD19 CAR T-cell therapy in autoimmune diseases. Kyverna aims to accelerate its neuroimmunology franchise and bring the first FDA-approved therapy to SPS patients and fundamentally change the treatment paradigm in MG.